Domain Therapeutics to Participate in Upcoming Investor and Industry Conferences
Strasbourg, France – Montreal, Canada, February 6th, 2023 – Domain Therapeutics (“Domain” or “the Company”), a drug discovery and development company focused on G Protein-Coupled Receptors (GPCRs) in immuno-oncology (IO), today announces investor and industry conferences that its Chief Executive Officer, Pascal Neuville, will attend or speak at in the first half of 2023.
OBIO Investor Summit, World Trade Centre, Toronto, Canada – 8-9 February
- Presentation slot: February 9th, 3:30 p.m., Room C/D
LSX World Congress, London, UK – 3-4 May
Bio€quity, Dublin, Ireland – 14-16 May
- Presentation slot: to be announced at a later date
– ENDS –
For more information, please contact:
Consilium Strategic Communications
Amber Fennell, Namrata Taak, Maya Bennison
Email: DomainTherapeutics@consilium-comms.com
Tel: +44 (0)20 3709 5813
NewCap (for French media)
Annie-Florence Loyer
Email: afloyer@newcap.fr
Tel: +33 (0)1.44.71.02.12
Download the pdf